期刊
UROLOGY
卷 72, 期 6, 页码 1319-1323出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.urology.2008.04.050
关键词
-
资金
- Department of the Army [W81XWH05-1-0375]
- Department of Health and Human Services (Health Resources and Services Administration) [C76HF00803]
- Department of Defense Uniformed Services University [MDA905-99-1-0003]
- Henry M. Jackson Foundation [600-06971000-236]
- Prostate Cancer Foundation
- National Institutes of Health [5P50CA089520-02]
- University of California, San Francisco
OBJECTIVES Previous research has demonstrated that patients with prostate cancer participating in the Prostate Cancer Lifestyle Trial had a reduction in prostate-specific antigen (PSA) levels, inhibition of LNCaP cell growth, and fewer prostate cancer-related clinical events at the end of 1 year compared with controls. The aim of this Study was to examine the clinical events in this trial during a 2-year period. METHODS The Prostate Cancer Lifestyle Trial was a 1-year randomized controlled clinical trial of 93 patients with early-stage prostate cancer (Gleason score <7, PSA 4-10 ng/mL) undergoing active Surveillance. The patients in the experimental arm were encouraged to adopt a low-fat, plant-based diet, to exercise and practice stress management, and to attend group Support sessions. The control patients received the usual care. RESULTS By 2 years of follow-up, 13 of 49 (27%) control patients and 2 of 43 (5%) experimental patients had undergone conventional prostate cancer treatment (radical prostatectomy, radiotherapy, or androgen deprivation, P < .05). No differences were found between the groups in other clinical events (eg, cardiac), and no deaths Occurred. Three of the treated control patients but none of the treated experimental patients had a PSA level of >= 10 ng/mL, and I treated control patient but no treated experimental patients had a PSA velocity of >2 ng/mL/y before treatment. No significant differences were found between the untreated experimental and untreated control patients in PSA change or velocity at the end of 2 years. CONCLUSIONS Patients with early-stage prostate cancer choosing active Surveillance might be able to avoid or delay conventional treatment for at least 2 years by making changes in their diet and lifestyle. UROLOGY 72: 1319-1323, 2008. (C) 2008 Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据